Alzheimer’s Disease: Experts Call For Changes in FDA Drug Approval Standards To Modernize Treatment

Alzheimer’s disease is a neurodegenerative disorder that results in dementia. Experts call for changes in FDA drug approval to modernize treatment.

A team of expert researchers on Alzheimer’s disease has recently published an analysis, "Single Endpoint for New Drug Approvals for Alzheimer's Disease," that urges the Food and Drug Administration (FDA) to clarify and modernize the current approach for approving new treatments.//

The analysis, authored by George Vradenburg, UsAgainstAlzheimer's Co-Founder and Chairman, and Drs. Howard Fillit, Dave Morgan, Marwan Sabbagh, Paul Aisen and Richard Mohs, recommends that the FDA approve new medicines that demonstrate a proven benefit on at least one therapeutic endpoint - either cognition or function.

Alzheimer’s disease - Causes, Symptoms, Diagnosis, Stages, Types, Prevention, Prognosis & Treatment
Alzheimer's disease is a progressive neurodegenerative disease affecting memory and thinking and making the person increasingly dependent on others.

‘Leading scientists call for changes in FDA drug approval standards to modernize treatment for Alzheimer’s disease.’

The current FDA standards require a new drug to show benefits on both proven endpoints, an unnecessarily challenging hurdle the authors say may be inhibiting investment in new Alzheimer's treatments.

The authors are members of ResearchersAgainstAlzheimer's (RA2), an UsAgainstAlzheimer's global network of more than 450 disease researchers.

"If the FDA were to state that meaningful efficacy on a single endpoint is sufficient for approval, we believe that it would impact prospective investments in this therapeutic area as well as clinical-trial design," wrote the authors.

Potential New Target for Alzheimer’s Disease Treatment
Possible molecular target that could be used for developing preventive treatment of Alzheimer’s disease is identified.

"We believe a clarified and modernized FDA approval standard for Alzheimer's disease would catalyze renewed investment in the discovery and development of new medical advances for Alzheimer's disease, particularly in early-stage companies and for venture investment."

The analysis points out that Alzheimer's disease biopharmaceutical research is lagging well behind that of other diseases, despite the fact that Alzheimer's diagnoses will triple in future decades and that there is no current means to prevent, treat or cure the disease.

Alzheimer's Risk Assessment Calculator
Alzheimer’s Risk Assessment Calculator is a tool to measure the level of Alzheimer’s disease. It also provides tips to prevent Alzheimer’s disease.

The analysis notes that in 2014-2015, there were only 135 ongoing interventional Alzheimer's disease clinical trials compared to nearly 5,000 similar trials for oncology drugs.

The authors wrote that a modernized FDA standard for Alzheimer's medications would reflect changes in the field and in treatment since the 1990s, and it would also align with draft guidance issued in 2013 for drug development for early Alzheimer's.

Quiz On Alzheimer’s Disease
Alzheimer’s disease (AD) is the most common form of dementia. Participate in this quiz to find out how much you know about this debilitating disease.

Specifically for Alzheimer's, the authors argue, if a new drug improves memory but has less positive impact on a patient's daily functioning skills, the medication should still meet standards for FDA approval, because clinically meaningful improvements in cognition matter importantly to persons with Alzheimer's independent of functional improvement and vice-versa.

"Irrespective of the degree of impact on secondary measures, the notion that the FDA would deny approval for a safe and well-tolerated drug candidate that achieves its primary endpoint of improving cognition in patients with Alzheimer's disease is almost unthinkable," the authors wrote.

The authors emphasized that the new standard is essential at a time in which recent clinical trial failures on Alzheimer's drugs have adversely affected investment in disease research.

The FDA has not approved a novel Alzheimer's treatment since 2003, and the 5.5 million Americans with Alzheimer's and their caregivers are desperate for innovation.

Source-Eurekalert